Global Humanized Mice Model Market Strategic Research Report

Scope of the Report

The global Humanized Mice Model market size is predicted to grow from US$ 140 million in 2025 to US$ 201 million in 2032; it is expected to grow at a CAGR of 5.2% from 2026 to 2032.

Humanized mice models are experimental animal models created by introducing human genes, cells, tissues, tumors, or microbiota into immunodeficient mice, thereby endowing the mice with specific "human biological characteristics." Broadly speaking, these models range from transgenic or knock-in mice expressing a specific human gene to models established through the transplantation of human peripheral blood mononuclear cells (PBMCs), human CD34+ hematopoietic stem cells, human thymic or hepatic tissues, or human tumor tissues. Their core value lies in enabling researchers to observe human immune responses, tumor growth, infection processes, and drug reactions within an *in vivo* environment, rather than relying solely on *in vitro* cell-based experiments.

The market is primarily driven by research demands in areas such as cancer immunotherapy, antibody drugs, bispecific antibodies, ADCs, CAR-T/TCR-T therapies, infectious diseases, and autoimmune disorders; consequently, pharmaceutical companies and CROs are increasingly seeking animal models that more closely mimic the human immune system, tumor microenvironment, and drug metabolism characteristics. In terms of product composition, the market encompasses genetically humanized mice, PBMC-humanized mice, CD34+ hematopoietic stem cell-humanized mice, and BLT models, with immune-system-humanized models and tumor-immunology-related models representing the fastest-growing segments. Geographically, North America remains the largest market, benefiting from a high concentration of major pharmaceutical companies, CROs, and research institutions; the European market is driven largely by needs in basic research and translational medicine; meanwhile, Asia-Pacific markets—including China and Japan—are experiencing rapid growth fueled by investments in innovative drug R&D, the expansion of the CXO industry, and the growth of local model animal companies. Regarding the competitive landscape, international players such as The Jackson Laboratory, Charles River, Taconic, Crown Bioscience, Champions Oncology, and genOway hold significant advantages in technology and customer base, while Chinese companies like Biocytogen, GemPharmatech and Cyagen are rapidly advancing in the fields of genetically humanized models and customized services. Future market growth will be primarily driven by the demand for more complex humanized models with higher translational value; however, the industry faces challenges such as long model-generation cycles, high costs, batch-to-batch variability, incomplete immune system reconstitution, ethical compliance issues, and experimental reproducibility concerns. Consequently, the focus of corporate competition is shifting from the supply of individual models toward comprehensive solutions that integrate model generation, efficacy evaluation, CRO services, and data platforms.

This report presents a comprehensive overview of the global Humanized Mice Model market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• PBMC Type
• HSC Type
• BLT Type
• Others

Segment by End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Segment by Application

• Tumors
• Infectious Diseases
• Autoimmune Diseases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Humanized Mice Model market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Tumors, Infectious Diseases, Autoimmune Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact